Cita APA (7a ed.)
O'Kane, G. M., Mesci, A. M., Chen, E. X., Bocaya, C. M., Jang, R. W., Wang, B. X., . . . Knox, J. J. (2025 Supplement 4). Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced HCC: A phase II study (PEMRAD). Journal of Clinical Oncology, 43, 602-734.
Cita Chicago Style (17a ed.)
O'Kane, Grainne M., et al. "Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects with Advanced HCC: A Phase II Study (PEMRAD)." Journal of Clinical Oncology 43 (2025 Supplement 4): 602-734.
Cita MLA (9a ed.)
O'Kane, Grainne M., et al. "Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects with Advanced HCC: A Phase II Study (PEMRAD)." Journal of Clinical Oncology, vol. 43, 2025 Supplement 4, pp. 602-734.
Precaución: Estas citas no son 100% exactas.